Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix (NASDAQ: OCUL) will report first-quarter 2026 financial results and host a live conference call and webcast on May 5, 2026 at 8:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) will report first-quarter 2026 financial results and host a live conference call and webcast on May 5, 2026 at 8:00 AM ET. The company will discuss business progress and results for the quarter ended March 31, 2026. A replay will be archived for at least 30 days.
Details
News Market Reaction – OCUL
On Apr 28, the day this news came out, OCUL closed 2.10% below the previous close.
Data tracked by StockTitan Argus for the Apr 28 session.
Key Figures
- Earnings call date
- May 5, 2026
- Scheduled Q1 2026 results conference call and webcast
- Earnings call time
- 8:00 AM ET
- Start time for Q1 2026 call
- Current price
- $9.52
- Pre-announcement trading level
- 52-week high
- $16.44
- OCUL trading <b>42.09%</b> below this level
- 52-week low
- $6.2301
- OCUL trading <b>52.81%</b> above this level
- 20-day avg volume
- 3,439,751
- Compared to today’s <b>2,545,839</b> shares
- Shelf filing date
- September 30, 2025
- Effective Form S-3ASR shelf registration
Historical Context
-
Planned May scientific and investor conference presentations including Phase 3 data.
-
Announcement of June 17, 2026 Investor Day with leadership and KOLs.
-
Equity inducement awards and options/RSUs granted to new employees and SVP.
-
Additional positive Week 52 SOL-1 Phase 3 AXPAXLI data in wet AMD.
-
Plans to present further SOL-1 Phase 3 data at April conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026.
Conference Call and Webcast Information:
Date: Tuesday, May 5, 2026 at 8:00 AM ET
Participant Dial-In (U.S.): 1-800-343-4136
Participant Dial-In (International): 1-203-518-9843
Conference ID: OCULAR (required for entry)
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.